dsco Discovery Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	4/21/2009 9:20:04 PM
	2 Recommendations Read Replies (2) of 318

One thing confuses me about the letter outlining the deficiencies of the DSCO Surfaxin fiasco. I thought that the time before the last approvable letter that the Biological Activity Test was under control as the FDA apparently only raised the CMC issue about the lipid contaminant. I do not incessantly follow the company, but paid attention to it as I did hold a significant amount of shares. As I posted last week, I had substantially but not completely sold out of my shares. Now is it that the company is not coming clean on the FDA statements, or that the FDA is being heavy handed with DSCO in part due to past transgressions and perhaps also the CEO who really has a big mouth that should be sewn shut or replaced. He spoke waaaaaaaay too much at the Monday am conference call, and he got into predicting the FDAs thoughts on Surfaxin. Even though I made significant denaros on this stock, I am really getting angry at the company mismanagement. Can anyone provide any color on the FDA position or on the veracity of the company's statements? TIA. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next